Abstract
Background There is a major need for information on pharmacokinetics (PK) of benznidazole in children with Chagas disease (CD). We present herein the results of a multicentre population PK, safety and efficacy study in children, infants and neonates with CD treated with BZN (100 mg and the 12.5 mg dispersible tablet, developed in a collaboration of DNDi and LAFEPE).
Methods 81 children 0-12 years of age were enrolled at 5 pediatric centers in Argentina. Diagnosis of T. cruzi infection was confirmed by direct microscopic examination or at least two positive conventional serologies. Subject enrolment was stratified by age: newborns to 2 years (minimum of 10 newborns) and >2-12 years. BNZ 7.5 mg/kg/d was administered in two daily doses for 60 days. Five blood samples per child were obtained at random times: at Day 0, at 2 – 5 h post-dose; during steady state, one sample at Day 7 and at Day 30; and two samples at 12 – 24 h after final BNZ dose at Day 60. The primary efficacy endpoint was parasitological clearance by qualitative PCR at the end of treatment.
Results Forty-one (51%) patients were under 2 years of age (including 14 newborns <1 month of age). Median age at enrolment was 22 months (mean: 43.2; interquartile range (IQR) 7-72 months). The median measured BNZ Cmax was 8.32 mg/L (IQR 5.95 – 11.8; range 1.79 – 19.38). Median observed BNZ Cmin (trough) concentration was 2 mg/L (IQR 1.25 – 3.77; range 0.14 – 7.08). Overall median simulated Css was 6.3 mg/L (IQR 4.7 – 8.5 mg/L). CL/F increased quickly during the first month of postnatal life and reached adult levels after approximately 10 years of age. Negative qPCR was observed at the end of treatment in all 76 patients who completed the treatment. Five patients discontinued treatment (3 due to AEs and 2 due to lack of compliance).
Conclusion We observed lower BNZ plasma concentrations in infants and children than those previously reported in adults treated with comparable mg/kg doses. Despite these lower concentrations, pediatric treatment was well tolerated and universally effective, with a high response rate and infrequent, mild AEs.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01549236
Funding Statement
DNDi received financial support for this work from the following donors: the Dutch Ministry of Foreign Affairs (DGIS), the Netherlands (grant number PDP15CH21) https://www.government.nl/ministries/ministry-of-foreign-affairs the Ministry of Health, Brazil (Cooperation agreement 2012) https://www.gov.br/saude/pt-br Associação Bem-Te-Vi Diversidade, Brazil (Grant 2013) https://www.facebook.com/BemTeViDiversidade/ Starr International Foundation, Switzerland (Grant 2015-1016) https://starrfoundation.org/ the Spanish Agency for International Development Cooperation (AECID), Spain (Grant 2007-2008) https://www.aecid.es/EN and the US Agency for International Development (USAID), via the 4th Sector Health Project, USA (Grant 2011) https://www.usaid.gov/. DNDi also thanks Médecins Sans Frontières International (Grant 2014-1018) https://www.msf.org/ the Swiss Agency for Development and Cooperation (SDC) Switzerland (Grant 81050394) https://www.eda.admin.ch/eda/en/fdfa/fdfa/organisation-fdfa/directorates-divisions/sdc.html and UK aid, UK (Grant 2013-2018) https://www.ukaiddirect.org/ for funding its overall mission. FGB was supported by the Argentine National Research Council (CONICET) https://www.conicet.gov.ar/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The study sponsor had a role in study design, analysis, and drafting/reviewing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Argentine National Drug, Food and Medical Technology Administration (ANMAT) and the Research Board and Ethics Board of each of the Network centers: Hospital de Niños Ricardo Gutiérrez de Buenos Aires, Hospital de Niños Doctor Hector Quintana de Jujuy, Hospital Público Materno Infantil de Salta, Centro de Chagas y Patología Regional de Santiago del Estero & Instituto Nacional de Parasitología Dr. Mario Fatala Chaben Buenos Aires.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Registered in clinicaltrials.gov #NCT01549236
Funding DNDi received financial support for this work from the following donors: the Dutch Ministry of Foreign Affairs (DGIS), the Netherlands (grant number PDP15CH21) https://www.government.nl/ministries/ministry-of-foreign-affairs; the Ministry of Health, Brazil (Cooperation agreement 2012) https://www.gov.br/saude/pt-br; Associação Bem-Te-Vi Diversidade, Brazil (Grant 2013) https://www.facebook.com/BemTeViDiversidade/; Starr International Foundation, Switzerland (Grant 2015-1016) https://starrfoundation.org/; the Spanish Agency for International Development Cooperation (AECID), Spain (Grant 2007-2008) https://www.aecid.es/EN; and the US Agency for International Development (USAID), via the 4th Sector Health Project, USA (Grant 2011) https://www.usaid.gov/. DNDi also thanks Médecins Sans Frontières International (Grant 2014-1018) https://www.msf.org/; the Swiss Agency for Development and Cooperation (SDC) Switzerland (Grant 81050394) https://www.eda.admin.ch/eda/en/fdfa/fdfa/organisation-fdfa/directorates-divisions/sdc.html; and UK aid, UK (Grant 2013-2018) https://www.ukaiddirect.org/ for funding its overall mission. FGB was supported by the Argentine National Research Council (CONICET) https://www.conicet.gov.ar/.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The study sponsor had a role in study design, analysis, and drafting/reviewing of the manuscript.
Data Availability
The data underlying the results of this study are available upon request because they contain potentially sensitive information. Interested researchers may contact the Drugs for Neglected Diseases initiative (DNDi), commissioner of this study, for data access requests via email at CTdata{at}dndi.org. Researchers may also request data by completing the form available at https://www.dndi.org/category/clinical-trials/. In this, they confirm that they will share data and results with DNDi and will publish any results open access.
